CA2972001C - GLUCAGON DERIVATIVES - Google Patents

GLUCAGON DERIVATIVES

Info

Publication number
CA2972001C
CA2972001C CA2972001A CA2972001A CA2972001C CA 2972001 C CA2972001 C CA 2972001C CA 2972001 A CA2972001 A CA 2972001A CA 2972001 A CA2972001 A CA 2972001A CA 2972001 C CA2972001 C CA 2972001C
Authority
CA
Canada
Prior art keywords
peptide
glucagon
obesity
amino acid
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2972001A
Other languages
English (en)
French (fr)
Other versions
CA2972001A1 (en
Inventor
Sung youb Jung
Young Jin Park
Jong Suk Lee
Jae Hyuk Choi
Chang Ki Lim
Se Chang Kwon
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of CA2972001A1 publication Critical patent/CA2972001A1/en
Application granted granted Critical
Publication of CA2972001C publication Critical patent/CA2972001C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2972001A 2014-12-30 2015-12-30 GLUCAGON DERIVATIVES Active CA2972001C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2014-0193691 2014-12-30
KR1020140193691A KR102418477B1 (ko) 2014-12-30 2014-12-30 글루카곤 유도체
PCT/KR2015/014481 WO2016108617A1 (en) 2014-12-30 2015-12-30 Glucagon derivatives

Publications (2)

Publication Number Publication Date
CA2972001A1 CA2972001A1 (en) 2016-07-07
CA2972001C true CA2972001C (en) 2024-07-02

Family

ID=56284668

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2972001A Active CA2972001C (en) 2014-12-30 2015-12-30 GLUCAGON DERIVATIVES

Country Status (18)

Country Link
US (3) US10513550B2 (cg-RX-API-DMAC7.html)
EP (1) EP3240802B1 (cg-RX-API-DMAC7.html)
JP (1) JP6758297B2 (cg-RX-API-DMAC7.html)
KR (1) KR102418477B1 (cg-RX-API-DMAC7.html)
CN (1) CN107250155B (cg-RX-API-DMAC7.html)
AR (1) AR103323A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015372767B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017013845A2 (cg-RX-API-DMAC7.html)
CA (1) CA2972001C (cg-RX-API-DMAC7.html)
EA (1) EA036479B1 (cg-RX-API-DMAC7.html)
IL (1) IL253001B (cg-RX-API-DMAC7.html)
MX (1) MX389593B (cg-RX-API-DMAC7.html)
PH (1) PH12017501205A1 (cg-RX-API-DMAC7.html)
SG (2) SG10201906912VA (cg-RX-API-DMAC7.html)
TW (1) TWI696631B (cg-RX-API-DMAC7.html)
UA (1) UA122967C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016108617A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201704328B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107636009B (zh) * 2014-12-30 2021-04-16 韩美药品株式会社 具有改善的稳定性的胰高血糖素衍生物
TWI713541B (zh) 2015-06-30 2020-12-21 南韓商韓美藥品股份有限公司 升糖素衍生物及包含該衍生物之長效接合物之組成物
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
HUE059737T2 (hu) 2015-12-31 2022-12-28 Hanmi Pharm Ind Co Ltd Glükagon, GLP-1 és GIP receptor aktiváló tripla aktivátor
WO2024038067A1 (en) 2022-08-18 2024-02-22 Boehringer Ingelheim International Gmbh Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
EP1060746A4 (en) 1998-03-06 2002-06-19 Chugai Pharmaceutical Co Ltd PROTEIN-FREE PREPARATIONS
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7217845B2 (en) 2002-11-25 2007-05-15 Sun Bio, Inc. Bifunctional polyethylene glycol derivatives
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
WO2005035761A1 (en) 2003-10-16 2005-04-21 Compugen Ltd. Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin
KR101135244B1 (ko) 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
US20090238838A1 (en) 2003-11-13 2009-09-24 Hanmi Pharm. Ind. Co. Ltd. Insulinotropic peptide conjugate using an immunoglobulin fc
RU2356909C2 (ru) 2003-11-13 2009-05-27 Ханми Фарм. Инд. Ко., Лтд. Белковый комплекс, полученный с использованием фрагмента иммуноглобулина, и способ получения такого комплекса
WO2006059106A2 (en) 2004-12-02 2006-06-08 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
BRPI0606992A2 (pt) 2005-02-11 2009-07-28 Amylin Pharmaceuticals Inc análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
EP1891105B1 (en) 2005-06-13 2012-04-11 Imperial Innovations Limited Oxyntomodulin analogues and their effects on feeding behaviour
GB0511986D0 (en) 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
US20090297496A1 (en) 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
AU2007221366B2 (en) 2006-02-22 2012-08-23 Msd Italia S.R.L. Oxyntomodulin derivatives
EP2046367A4 (en) 2006-06-07 2009-11-11 Human Genome Sciences Inc ALBUM INFUSION PROTEINS
KR100880509B1 (ko) 2006-10-16 2009-01-28 한미약품 주식회사 재조합 단백질의 대량 생산을 위한 신규한 벡터, 발현세포주 및 이를 이용한 재조합 단백질의 생산 방법
GB0624868D0 (en) 2006-12-13 2007-01-24 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
MX2009008241A (es) 2007-02-15 2009-10-08 Univ Indiana Res & Tech Corp Co-agonistas de receptor de glucagon/glp-1.
NZ582480A (en) 2007-07-10 2011-03-31 Lilly Co Eli Glp-1-fc fusion protein formulation
JP5345617B2 (ja) 2007-07-27 2013-11-20 バイエル・クロップサイエンス・アーゲー 三元活性化合物組合せ
EP2187525B1 (en) 2007-08-07 2014-03-12 Fujitsu Limited Error detection device, and error correction/error detection decoding device and method
EP2197470A2 (en) 2007-09-11 2010-06-23 Mondobiotech Laboratories AG Use of bubuc and optionally eaa-mart1 (26-35) as a therapeutic agent for the treatment of hcmv infections
US8980830B2 (en) * 2007-10-30 2015-03-17 Indiana University Research And Technology Corporation Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity
CN101918027A (zh) 2007-11-02 2010-12-15 森托科尔奥索生物科技公司 半合成GLP-1肽-Fc融合构造、方法及其用途
CA2713348C (en) 2008-01-30 2018-10-09 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
AR072160A1 (es) * 2008-06-17 2010-08-11 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
WO2009155257A1 (en) 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
WO2010013012A2 (en) 2008-08-01 2010-02-04 Lund University Bioscience Ab Novel polypeptides and uses thereof
US20110171312A1 (en) 2008-09-19 2011-07-14 Nektar Therapeutics Modified therapeutic peptides, methods of their preparation and use
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
FR2936441B1 (fr) 2008-09-26 2012-12-07 Rhodia Operations Article polyamide composite
WO2010070253A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
AU2009327418A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
JP5843357B2 (ja) 2009-02-03 2016-01-13 アムニクス オペレーティング インコーポレイテッド 延長組換えポリペプチドおよび延長組換えポリペプチドを含む組成物
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
CA3018235C (en) 2009-03-20 2021-01-12 Amgen Inc. Carrier immunoglobulins and uses thereof
HRP20161055T1 (hr) 2009-03-20 2016-11-04 Hanmi Science Co., Ltd. Postupak proizvodnje konjugata specifičnog za mjesto od fiziološki djelotvornog polipeptida
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
HUE026255T2 (en) 2009-07-13 2016-06-28 Zealand Pharma As Acylated glucagon analogues
US20120294855A1 (en) 2009-11-03 2012-11-22 Eli Lilly & Company Glp-1 receptor agonist compounds for obstructive sleep apnea
EP2509997B1 (en) 2009-12-07 2017-08-30 i2 Pharmaceuticals, Inc. Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
AR079345A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina
AR079344A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
MX342409B (es) * 2010-01-20 2016-09-28 Zealand Pharma As Tratamiento de enfermedades cardiacas.
US8551946B2 (en) 2010-01-27 2013-10-08 Indiana University Research And Technology Corporation Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
AU2011231503C1 (en) * 2010-03-26 2016-03-03 Novo Nordisk A/S Novel glucagon analogues
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
US9145451B2 (en) 2010-05-13 2015-09-29 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhbiting G protein coupled receptor activity
RU2580317C2 (ru) 2010-06-24 2016-04-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов
KR101337797B1 (ko) 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
WO2012032567A1 (ja) 2010-09-06 2012-03-15 パナソニック株式会社 表示装置及びその制御方法
CN101974077A (zh) 2010-09-15 2011-02-16 南京瑞年天平医药科技有限公司 一种新颖的多肽化合物
KR101303388B1 (ko) 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
KR101767570B1 (ko) 2010-10-26 2017-08-14 한미사이언스 주식회사 항 비만 펩타이드의 지속형 결합체
CN102010473A (zh) 2010-11-10 2011-04-13 曹鹏 重组胃泌酸调节素融合蛋白及其制备和应用
KR20140020851A (ko) 2010-12-22 2014-02-19 마르카디아 바이오테크, 인코퍼레이트 Gip 및 glp-1 수용체-활성 글루카곤계 펩타이드를 이용한 대사장애 및 비만의 치료방법
EP2492749A1 (en) 2011-02-28 2012-08-29 Rohm and Haas Electronic Materials LLC Photoresist compositions and methods of forming photolithographic patterns
KR101161526B1 (ko) 2011-05-16 2012-07-02 숭실대학교산학협력단 연료전지용 촉매전극을 위한 코어/쉘 구조의 나노 지지체 및 그 제조방법
SI2718318T1 (sl) 2011-06-10 2018-11-30 Hanmi Science Co., Ltd. Novi derivati oksintomodulina in le-te obsegajoča farmacevtska sestava za zdravljenje debelosti
ES2710356T3 (es) 2011-06-17 2019-04-24 Hanmi Science Co Ltd Conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
CN103748109A (zh) 2011-06-22 2014-04-23 印第安纳大学研究及科技有限公司 胰高血糖素/glp-1受体共同激动剂
KR101665009B1 (ko) 2012-03-09 2016-10-11 한미사이언스 주식회사 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
SG11201406671RA (en) 2012-04-19 2014-11-27 Opko Biolog Ltd Long-acting oxyntomodulin variants and methods of producing same
EP2864351B1 (en) * 2012-06-21 2016-08-10 Indiana University Research and Technology Corporation Glucagon analogs exhibiting gip receptor activity
KR101373563B1 (ko) 2012-07-25 2014-03-12 전북대학교산학협력단 Ｔｏｆ-ｍｒａ를 이용한 혈류특성 및 ｍｒ-신호강도구배(전단율) 유도방법
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
WO2014049610A2 (en) * 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
TWI652071B (zh) 2012-11-06 2019-03-01 韓美藥品股份有限公司 包含調酸素及免疫球蛋白片段之蛋白質接合物的液態製劑
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
PL2986313T3 (pl) * 2013-04-18 2019-12-31 Novo Nordisk A/S Stabilni, dłużej działający współagoniści receptora glp-1/glukagonu do zastosowań medycznych
JP6137046B2 (ja) 2014-05-09 2017-05-31 信越化学工業株式会社 単量体、高分子化合物、レジスト材料及びパターン形成方法
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
WO2019171352A2 (en) 2018-03-08 2019-09-12 Janssen Pharmaceutica Nv Methods of treating severe non-diabetic obesity

Also Published As

Publication number Publication date
US20220025012A1 (en) 2022-01-27
US20200140515A1 (en) 2020-05-07
EA036479B1 (ru) 2020-11-16
IL253001B (en) 2022-04-01
NZ733649A (en) 2024-07-26
AU2015372767B2 (en) 2020-07-16
BR112017013845A2 (pt) 2018-01-02
UA122967C2 (uk) 2021-01-27
SG10201906912VA (en) 2019-09-27
EP3240802B1 (en) 2021-07-21
AU2015372767A1 (en) 2017-07-13
PH12017501205A1 (en) 2017-10-18
TW201632546A (zh) 2016-09-16
US12018060B2 (en) 2024-06-25
SG11201705130XA (en) 2017-07-28
CA2972001A1 (en) 2016-07-07
HK1246323A1 (en) 2018-09-07
CN107250155A (zh) 2017-10-13
ZA201704328B (en) 2021-01-27
EP3240802A1 (en) 2017-11-08
TWI696631B (zh) 2020-06-21
US20180002395A1 (en) 2018-01-04
AR103323A1 (es) 2017-05-03
MX2017008715A (es) 2017-11-17
CN107250155B (zh) 2021-08-10
US10513550B2 (en) 2019-12-24
KR102418477B1 (ko) 2022-07-08
EP3240802A4 (en) 2018-10-10
EA201791498A1 (ru) 2017-10-31
NZ771617A (en) 2024-09-27
US11254724B2 (en) 2022-02-22
WO2016108617A1 (en) 2016-07-07
KR20160082026A (ko) 2016-07-08
MX389593B (es) 2025-03-20
JP2018505153A (ja) 2018-02-22
IL253001A0 (en) 2017-08-31
JP6758297B2 (ja) 2020-09-23

Similar Documents

Publication Publication Date Title
AU2020201322B2 (en) Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
US12018060B2 (en) Glucagon derivatives
HK1246323B (en) Glucagon derivatives
HK40002934A (en) Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
NZ618810B2 (en) Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
NZ733464A (en) Glucagon derivatives with improved stability
NZ755534B2 (en) Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
NZ748012B2 (en) Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
NZ734808B2 (en) Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
NZ740049B2 (en) Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201204

EEER Examination request

Effective date: 20201204

EEER Examination request

Effective date: 20201204

EEER Examination request

Effective date: 20201204

EEER Examination request

Effective date: 20201204

EEER Examination request

Effective date: 20201204

EEER Examination request

Effective date: 20201204

EEER Examination request

Effective date: 20201204